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Introduction: Extrapleural pneumonectomy (EPP) with adjuvant
radiotherapy may be used to treat malignant pleural mesothelioma.
Radiation pneumonitis, felt to be related to contralateral lung radi-
ation dose, may affect patient mortality in this setting. Two standard
therapeutic approaches currently used to deliver adjuvant radiother-
apy were compared in this study: intensity modulation radiation
treatment (IMRT) with a planned dose of 45 Gray (Gy) and a
modified electron-photon technique delivering 54 Gy.
Methods: Treatment plans of 10 mesothelioma patients who under-
went EPP and hemithoracic IMRT to a total dose of 45 Gy were
analyzed. Plans using a combination of opposed anterior posterior
radiation fields and electron supplementation (electron-photon tech-
nique EPT) to a total dose of 54 Gy were then generated and
compared with IMRT plans.
Results: Dosimetric comparison revealed a significant reduction in
contralateral lung dose with EPT versus IMRT, even with increased
prescription dose used with EPT plans. Median heart and contralateral
kidney doses were also significantly reduced with EPT versus IMRT.
Dose coverage of planning target volume and doses to spinal cord, liver,
and ipsilateral kidney were similar with use of the two techniques.
Conclusions: Our data suggest that hemithoracic radiotherapy de-
livered after EPP using EPT may minimize dose to contralateral
lung and other structures when compared with IMRT, without
compromise of planning target volume coverage.
Key Words: Hemithoracic IMRT, Radiotherapy after extrapleural
pneumonectomy, Radiotherapy in treatment of mesothelioma, Ra-
diation pneumonitis.
(J Thorac Oncol. 2009;4: 1431–1437)
Malignant pleural mesothelioma is a rare, aggressivetumor that arises from the pleural lining of the lung. It
is associated with median survival rates of 4 to 12 months,1
and death is nearly always due to local progression, with
hematogenous spread usually occurring only very late in the
disease course. Extrapleural pneumonectomy (EPP) is an
aggressive surgical approach used by some centers as primary
treatment for malignant pleural mesothelioma (MPM) but has
not been demonstrated to increase overall survival (OS) when
used alone.2–4 The addition of radiation treatment (RT) and
chemotherapy to EPP has potential to provide improvement
in OS for patients with MPM; however, even after trimodality
treatment, the ipsilateral hemithorax remains the most com-
mon site of first failure.5 Additionally, local factors such as
close or positive margins after EPP have been shown to
impact survival.6 For these reasons, attention to improved
local control is particularly important.
Many centers make use of hemithoracic RT after EPP
in attempt to improve local control rates, delivering RT
through several described techniques, including intensity-
modulated radiotherapy (IMRT), conventional use of photon
and electron beams, and combinations of these.7–10 Although
in vitro work has demonstrated MPM cells to be radiosensi-
tive11 and higher RT doses have been demonstrated to im-
prove local control rates,12,13 RT dosing and delivery are
complicated by the proximity of numerous vital organs and
structures, including the contralateral lung, heart, kidneys,
spinal cord, esophagus, and liver, to the regions at risk for
residual disease. Recently, significant morbidity and mortal-
ity rates have been reported with use of IMRT after EPP,
including a nearly 50% rate of fatal pneumonitis in one cohort
of patients.14 Contralateral lung dosing parameters, including
volume of lung receiving 5 Gray (Gy) (V5), volume of lung
receiving 20 Gy (V20), and mean contralateral lung dose
have been demonstrated to be important factors in the devel-
opment of pneumonitis and pulmonary-related death.14,15
In light of demonstrated local recurrence risk, which is
likely affected by achievable RT dose after EPP, as well as
morbidity and mortality risk associated with delivery of this
RT, maximizing dose to structures at risk for recurrence
while minimizing dose to contralateral lung and other organs
would be expected to improve OS for patients with MPM.
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This dosimetric study was undertaken to compare two differ-
ent treatment delivery techniques that are currently being
used to deliver postoperative hemithoracic RT after EPP for
patients with MPM: hemithoracic IMRT and use of opposed
anterior-posterior/posterior-anterior (AP-PA) photon fields with
electron supplementation (electron-photon technique EPT).
METHODS
The purpose of this study was to compare two different
treatment techniques that are currently being used to deliver
hemithoracic RT after EPP. The EPT technique uses a combi-
nation of photon beam arrangements with matched electron
beams to deliver a total prescription dose of 54 Gy in 1.8 Gy per
fraction.10 The IMRT technique used during the study period at
our institution used multiple intensity modulated photon beams
to deliver 45 Gy to the planning target volume (PTV).
Treatment plans were reviewed for 10 patients diag-
nosed with MPM and treated with EPP followed by hemitho-
racic IMRT at the Hospital of the University of Pennsylvania
between 2003 and 2006. Five patients were treated for left-
sided tumors and five for right-sided tumors; of these, three
were women and seven were men. EPP consisted of resection
of the entire ipsilateral lung and parietal pleura, ipsilateral
pericardium, and ipsilateral hemidiaphragm with subsequent
reconstruction of the hemidiaphragm with Gore-Tex, so that
abdominal contents were maintained within the abdominal
cavity. Resection margins were marked with radioopaque
surgical clips. After postoperative recovery, patients under-
went treatment planning computed tomographic simulation
without intravenous contrast. Patients were positioned supine
with arms above the head, and axial helical computed tomog-
raphy images of 3 mm thickness were acquired. Wires were
placed on scars and drain sites to facilitate radiation planning.
In a multidisciplinary setting involving both the radiation
oncologist and the thoracic surgeon, the PTV was delineated,
encompassing the ipsilateral chest cavity and wall, as well as
the adjacent abdomen, including the diaphragmatic insertion,
crura, and pleural reflection (Figure 1). Surgical clips were
included in the PTV and were used to facilitate PTV volume
delineation. Skin was included in the PTV in the region of
surgical scars, including drain sites, and 1 cm bolus was
applied to scar regions to facilitate adequate dosing. PTV
extended from the level of the thoracic inlet through the
midabdomen or lowest level of diaphragmatic insertion as
defined by surgical clip placement. Organs at risk (OAR),
including contralateral lung, esophagus, heart, liver, spinal
cord, and bilateral kidneys, were also delineated. The PTV
was prescribed to receive 45 Gy in 1.8 Gy fractions delivered
daily. Mean contralateral lung dose was constrained to be 9
Gy, with contralateral lung V5 and V20 (volume receiving 5
and 20 Gy, respectively) constrained to 60% and 20%,
respectively. Dose and volume constraints consistent with
standard allowances were imposed on other OAR (Table 1).
Treatment plans were generated using Oncentra Treat-
ment Planning software, and treatment was delivered by
Siemens linear accelerators using 6 MV photon beams. Sev-
eral optimization iterations were required for each patient; the
plan delivering the optimal PTV dose while best meeting the
described organ constraints was ultimately chosen for each
patient. Reduction of contralateral lung dose was given high
priority during IMRT optimization with regard to beam
angles; however, beam angles were not standardized due to
anatomic variation requiring different beam arrangements to
optimize dose delivery for each patient. Seven to nine beams
were used depending on plan optimization (Figure 2). Of
note, the first four patients in our study had been treated in an
era when more relaxed organ constraints were used; these
four cases were replanned using the above constraints for the
purposes of this study. Two of 10 patients required a split-
field IMRT single-isocenter technique with matched beams
because the treatment length exceeded 40 cm in the cranio-
caudal axis, the maximal aperture available on our linear
accelerators.
The same 10 cases were replanned using a EPT tech-
nique described previously10 (Figure 3). Field borders for
opposing AP-PA photon fields were placed at the upper
border of T1 superiorly, the lower border of L2 inferiorly, the
contralateral edge of the vertebral body medially, and flash-
ing skin laterally. It should be noted that, in practice, no PTV
is defined in the EPT technique; in this study, the dose to the
PTV as defined for IMRT planning described earlier was
assessed. A custom Cerrobend abdominal block was placed
in each field to shield the stomach/liver and ipsilateral kidney
from the outset of treatment. The total prescribed dose was 54
FIGURE 1. Planning target vol-
ume (PTV) used for intensity-
modulated radiotherapy (IMRT)
planning for hemithoracic radio-
therapy after extrapleural pneu-
monectomy. PTV included the
entire chest cavity and chest
wall and adjacent abdomen
from the level of the thoracic
inlet to the diaphragmatic inser-
tion as delineated by surgical
clips. Treatment volumes were
extended to encompass skin in
regions of scar and drain sites.
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Gy in 1.8 Gy fractions. This dose was chosen for this study
as it is the dose that has been previously published and is used
in current clinical practice.10 The photon beam portion of the
treatment was prescribed to midplane. The areas of the
abdominal blocks were supplemented with en face electron
fields. The daily electron dose was 1.53 Gy prescribed to the
90% isodose line, to a depth encompassing the chest wall;
this dose was based on a previously published calculation of
15% scatter contribution under the blocks from the photon
fields.10 During treatment of the left hemithorax only, an anterior
block was placed over the heart at a cumulative dose of 19.8 Gy,
and the blocked area subsequently delivered 1.53 Gy daily
through an en face electron field. At a dose of 41.4 Gy, anterior
and posterior blocks were placed over the spinal cord.
Dose volume histograms and isodose lines were com-
pared for the two techniques in the case of each patient. Dose
and volume parameters for PTV, contralateral lung, heart,
liver, spinal cord, and ipsilateral and contralateral kidneys
were determined for each case. Values for all 10 patients
were compared using a two-tailed Student’s t test.16 All
values were considered significant if p  0.05. Error bars
were determined based on standard error of the mean.
RESULTS
Both techniques seemed to allow for similar and ade-
quate PTV coverage: the average PTV volume receiving 95%
of the prescribed dose was not significantly different between
the two techniques (80% for EPT versus 81% for IMRT, p 
0.8). As described earlier, the PTV was prescribed to receive
a total dose of 54 Gy in the EPT plans versus 45 Gy which
was prescribed in the IMRT plans; this discrepancy was
maintained to compare the technique with which our patients
were actually treated with a different technique as described
in the literature. Although prescribed doses were different for
the two techniques, the percent of the prescribed dose re-
ceived by 90%, 80%, 70%, and 50% of the PTV did not differ
significantly between the two techniques (Figure 4). Absolute
doses, of course, did differ: average median dose to PTV was
58.6 Gy (range, 55.5–61.8 Gy) with the EPT technique
versus 48.2 Gy (range, 44.3 Gy–53.3 Gy) with IMRT (p 
0.0001). Similarly, average doses to 90%, 80%, and 70% of
the PTV were 46.8 Gy (range, 40.3–56.8 Gy), 53.0 Gy
(range, 47.7–56.4 Gy), and 56.4 Gy (range, 52.1–60.0 Gy)
with EPT versus 41.8 Gy (range, 25.9–50.2), 43.6 Gy (range,
FIGURE 2. Sample beam arrangement and dose distribution for delivery of intensity-modulated radiation therapy (IMRT) to
the (A) left and (B) right hemithorax after extrapleural pneumonectomy in treatment of malignant mesothelioma. Treatment
consisted of delivery of 45 Gray (Gy) in daily fractions of 1.8 Gy to the planning target volume (PTV).
TABLE 1. Constraints Applied for Organs at Risk During
Intensity-Modulated Radiotherapy (IMRT) Planning
Organ at Risk Constraint
Spinal cord Maximum dose 50 Gy
90% 45 Gy
Esophagus Maximum dose 60 Gy
70% 55 Gy
Contralateral lung Mean dose 9 Gy
V5* 60 Gy
V20* 20 Gy
Heart Maximum dose 60 Gy
70% 45 Gy
80% 50 Gy
Liver 50% 30 Gy
Kidney (each) 50% 18 Gy
*V5 and V20 refer to volume of lung receiving 5 and 20 Gy, respectively.
Gy, Gray.
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28.5–50.4 Gy), and 45.4 Gy (range, 35.9–52.0 Gy) with
IMRT, respectively; as expected, differences in absolute PTV
dose were statistically significant (p  0.03, p  0.001, and
p  0.0001 for average dose to 90%, 80%, and 70%,
respectively). Significantly more inhomogeneity seemed to
be present with use of the EPT technique, with a signifi-
cantly higher volume receiving 105% of the planned dose
with EPT versus IMRT (mean 56% range, 31–73%
versus mean 36% range, 18–69% with EPT versus
IMRT, respectively, p  0.01).
The average contralateral lung V5 was 18% (range,
3–36%) with EPT versus 64% (range, 49–69%) with IMRT
(p  0.0001), and average contralateral lung V20 was 5%
(range, 0.2–19%) versus 12% (range, 3–21%) with EPT
versus IMRT, respectively (p 0.02) (Figure 5). The average
mean contralateral lung dose was 4.2 Gy with EPT (range,
2.2–7.3 Gy) versus 9.1 Gy with IMRT (range, 7.6–14.1 Gy)
(p  0.001) (Figure 6).
The average median dose to the contralateral kidney
was 1.9 Gy with EPT (range, 1.4–3.1 Gy) versus 8.2 Gy
(range, 4.1–11.9) with IMRT (p  0.0001) (Figure 6). The
average median dose to the ipsilateral kidney did not differ
significantly between the two techniques (16.1 Gy, range
4.9–29.9 Gy, versus 21.3 Gy, range 6.6–43.9 Gy with EPT
versus IMRT, respectively, p  0.37) (Figure 6). Average
maximum spinal cord dose did not differ significantly be-
FIGURE 4. Average percent of prescribed dose to planning
target volume with electron-photon technique (EPT) versus
intensity-modulated radiotherapy (IMRT) during hemitho-
racic radiotherapy after extrapleural pneumonectomy.
FIGURE 5. Average contralateral lung volume receiving
dose of 5 Gray (Gy) and 20 Gy with electron-photon tech-
nique (EPT), prescribed to 54 Gy, versus intensity-modulated
radiotherapy (IMRT), prescribed to 45 Gy, during hemitho-
racic radiotherapy after extrapleural pneumonectomy.
FIGURE 3. Field and block arrangements employed with
use of combined electron-photon technique for hemitho-
racic radiotherapy after extrapleural pneumonectomy. The
total prescribed dose from the anterior-posterior (AP-PA)
photon fields and supplemental electron fields was 54 Gray
(Gy) in 1.8 Gy fractions. At the initiation of treatment,
blocks were placed in the region of the abdomen. During
treatment of the left hemithorax, an anterior block was
placed over the heart at 19.8 Gy. Blocked areas were subse-
quently delivered 1.53 Gy daily through an en face electron
field. At 41.4 Gy, anterior and posterior blocks were placed
over the spinal cord.
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tween the two techniques (36.7 Gy with EPT versus 40.9 Gy
with IMRT, p  0.17).
For the five patients treated for left-sided tumors, av-
erage median dose to the heart was 37.2 Gy (range, 31.7–41.0
Gy) with EPT versus 42.5 Gy (range, 40.8–45.1 Gy) with
IMRT (p  0.02) (Figure 6). Average median dose to liver
for the five patients treated for right-sided tumors was 35.2
Gy (range, 13.8–55.1 Gy) with EPT versus 31.7 Gy (range,
28.6–36.6 Gy) with IMRT (p  0.6) (Figure 6).
DISCUSSION
This dosimetric analysis was performed to evaluate the
potential for two different techniques to deliver tumoricidal
radiation dose to the hemithorax after EPP in patients with
MPM while reducing risk of life-threatening radiation-related
complications resulting from increased dose to nearby vital
organs. Our data suggest that both of the techniques evalu-
ated, IMRT and EPT, likely allow adequate dosing of the
PTV; however, doses to contralateral lung, contralateral kid-
ney, and heart seem to be significantly reduced with the EPT
technique when compared with IMRT, whereas dose to spinal
cord, ipsilateral kidney, and liver remain similar.
MPM is a rare disease associated with a dismal prog-
nosis. EPP is an aggressive surgical approach used by some
centers as primary treatment for MPM that involves en bloc
resection of the ipsilateral lung, pleura, hemidiaphragm, and
pericardium and associated pericardial fat. The diffuse nature
of MPM places the ipsilateral chest wall, diaphragmatic
insertion, pericardium, mediastinum, and bronchial stump at
risk for disease recurrence following this procedure. Likely as
a result, EPP alone has not been shown to improve survival
rates.2–4 Death from MPM usually results from local progres-
sion, and the ipsilateral hemithorax remains the most com-
mon site of first failure after surgical resection with EPP. This
risk is increased particularly for patients with close or posi-
tive surgical margins after EPP. For this reason, efforts by
several centers have focused on developing RT techniques
that allow delivery of tumoricidal radiation dose to address
microscopic disease foci that remain after EPP. Recently,
significant morbidity and mortality have been described due
to radiation pneumonitis after hemithoracic RT, and the risk
of severe pulmonary toxicity seems to be related to dose and
volume parameters of the contralateral lung. Several other
vital organs also remain at risk for severe, potentially life
threatening, toxicity that may result from hemithoracic RT.
Our analysis demonstrates similar PTV coverage using
either the EPT or the IMRT techniques. Although the pre-
scribed PTV dose differed in this study for the two techniques
used, the PTV volume receiving 95% of the prescribed dose,
as well as the percent of the prescribed dose received by 90%,
80%, 70%, and 50% of the PTV, did not differ significantly
between the two techniques. Several groups have published
results with IMRT PTV prescription between 50 and 54
Gy8,17,18 and have demonstrated that this dose prescription is
possible with an IMRT technique and similar OAR con-
straints to those used in this study. Because there has histor-
ically been no PTV defined in the EPT technique, when it has
been used clinically, this report represents the first to quantify
the true dose delivered to the region of the hemithorax at
greatest risk for local failure as defined by the PTV using
EPT, and PTV coverage with EPT seems to be adequate.
Given that either technique may likely be used to
deliver adequate PTV coverage, we must turn our attention to
dose to the many OAR for damage from hemithoracic radio-
therapy. Our study demonstrates that the mean contralateral
lung dose, as well as the contralateral lung V5, and V20 can
be significantly reduced with use of the EPT technique, and
this finding has been documented by other groups.18 Efforts
to reduce contralateral lung dose using increasingly restricted
IMRT techniques have resulted in decreases in V5, V20, and
mean lung dose, but these values, most notably the V5,
remain higher with IMRT than those demonstrated here and
by other groups with use of the EPT technique.17 Although
the clinical impact of these differences remain uncertain, the
V5, V20, and mean lung dose have been shown by several
groups to contribute to risk of potentially fatal lung toxicity
FIGURE 6. Dose to organs at risk
with electron-photon technique
(EPT) versus intensity-modulated
radiotherapy (IMRT) for hemitho-
racic radiotherapy after extrapleural
pneumonectomy. *Median heart
dose for only patients receiving
left-sided treatment (n  5). **Me-
dian liver dose for only patients
receiving right-sided treatment
(n  5). CL, contralateral lung; IK,
ipsilateral kidney; and CK, con-
tralateral kidney.
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and should be minimized as much as possible. After EPP,
because no lung remains in the ipsilateral hemithorax, dose
deposited in this region does not contribute to pneumonitis
risk; rather, pushing dose into the ipsilateral hemithorax to
minimize or eliminate dose to contralateral lung should in
turn minimize or eliminate the risk of radiation-induced
pneumonitis. This stands in contrast to treatment of patients
who have not undergone EPP but instead more limited
surgery such as pleurectomy/decortication. In these instances,
when the ipsilateral lung remains present within the hemitho-
rax, delivering dose to the underlying lung could potentially
cause pneumonitis and IMRT offers clear benefit for deliv-
ering dose to the “rind” of the chest wall while minimizing
dose to the chest cavity where lung tissue remains.
Our data also demonstrate significantly decreased car-
diac dose with EPT versus IMRT in the patients treated for
left-sided tumors. Although the clinical impact of reducing
cardiac radiation dose in patients with mesothelioma has not
been studied to our knowledge, increased cardiac morbidity
and mortality attributable to radiation exposure has certainly
been demonstrated in other disease sites.19–21 Perhaps most
importantly, decreasing cardiac dose during RT to the medi-
astinum has recently been demonstrated to reduce the risk of
acute cardiac toxicity21 and late cardiac effects. In patients
with MPM, who have already undergone major surgical
procedure and difficult RT, acute effects such as pericardial
effusion may significantly detract from quality of life, and
prevention or risk reduction seems particularly important. For
this reason, reduction of cardiac dose will undoubtedly be in
the best interests of our patients, and our data demonstrate
lower cardiac dosing with EPT over IMRT.
In addition, significant reduction in contralateral kidney
dose with EPT versus IMRT is evident and potentially clin-
ically important. Although impact of renal radiation dose in
treatment of mesothelioma has not been specifically studied,
data in other disease sites demonstrate a relationship between
total dose and incidence of late renal toxicity.22 Contralateral
kidney dose may be particularly important in the setting of
mesothelioma, when radiation to the hemithorax may render
the ipsilateral kidney unavoidably damaged. Furthermore,
patients with MPM may receive any number of nephrotoxic
drugs during the course of diagnosis, surgical treatment, and
adjuvant treatment, including contrast dye, antibiotics, anti-
fungals, and platinum-containing chemotherapeutics. All
these factors underscore the importance of minimizing radi-
ation dose to the contralateral kidney; our data demonstrate
that this may be possible with use of EPT, when compared
with IMRT.
Within our study, reduction of radiation dose to the
contralateral lung, heart, and contralateral kidney seems to be
possible with use of an EPT technique versus IMRT, even
when EPT plans are prescribed to a higher dose than IMRT
plans. These benefits seem to be feasible with neither reduc-
tion of PTV coverage nor increase in dose to other vital
organs including liver, ipsilateral kidney, and spinal cord. Of
course, the potential for further optimization with varied
beam arrangements using IMRT may allow for decreased
cardiac, contralateral lung, and contralateral kidney dose,17
and further study of IMRT technique for MPM after EPP
could certainly equalize this factor between IMRT and EPT.
In addition, IMRT techniques may allow for simultaneous
“boosting” or delivery of higher radiation dose to regions at
particular risk for local failure after EPP (e.g., positive sur-
gical margins), and this may contribute to improved local
control. However, even in this setting, use of an EPT tech-
nique in combination with IMRT to deliver higher doses to
at-risk regions may allow reduction of dose to the contralat-
eral lung and other organs without sacrifice of PTV coverage.
Our study is limited by its very nature as a dosimetric
analysis, in that clinical outcomes are not available from this
data. Additionally, as described earlier, PTV dosing was
different between the two techniques described. Our analysis
was undertaken despite this difference in dosing to preserve
the integrity of IMRT plans used for patient treatment and to
compare them accurately to a previously described technique
for EPT treatment. Finally, concerns regarding potential in-
creased risk of set-up error with the EPT technique compared
with IMRT are certainly valid and are not addressed in this
study. The EPT technique is quite complicated to execute and
use may increase risk of over and/or underdosing in regions
of photon/electron match; these issues are evidenced in this
study by the increased inhomogeneity and higher volumes of
overdosing observed with the EPT technique. The complex
nature of the EPT technique when compared with IMRT may
well offset some of the potential benefit that it might provide.
A clinical comparison in the form of a randomized, con-
trolled, clinical trial would address these issues; however,
given the significant differences in the two techniques, com-
pounded by the relative rarity of MPM, such a trial is unlikely
to be performed.
As radiotherapy techniques continue to evolve, our
ability to treat large regions of tissue with improved confor-
mality will undoubtedly improve. However, as we approach
new technologies, the potential benefits of performing
hemithoracic RT with an AP-PA technique should be kept in
mind. This may prove to be particularly important as the
potential use of proton beam therapy becomes available. For
patients who have undergone EPP, protection, and in turn
minimal RT exposure of the contralateral lung is of para-
mount importance. The use of an AP-PA technique may
allow relative sparing of the contralateral lung and other
structures when compared with other techniques. Potentially,
use of proton beams could prevent the need for blocking of
normal structures with this technique, eliminating the inher-
ent risks of set-up error and under and overdosing in regions
of matching photon and electron fields. The particulate nature
of protons used for RT should allow even further reduction in
cardiac, kidney, and liver dose as well.
Several different techniques exist for delivery of
hemithoracic RT after EPP in patients with MPM. This
dosimetric study demonstrates a decrease in dose to several
OAR, particularly the contralateral lung, without sacrifice of
PTV coverage, with an EPT technique over an IMRT tech-
nique. This improvement in dose distribution to vital organs
would be expected to reduce morbidity and mortality associ-
ated with hemithoracic RT and to potentially improve out-
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comes for patients with mesothelioma. Furthermore, this
technique may be used with newer technologies, such as
proton beams, as availability becomes more widespread.
REFERENCES
1. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the
pleura in Ontario and Quebec: a retrospective study of 332 patients.
J Clin Oncol 1989;7:1157–1168.
2. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonec-
tomy in the management of diffuse malignant mesothelioma of the
pleura. Experience with 29 patients. Thorax 1976;31:15–24.
3. Jaklitsch MT, Grondin SC, Sugarbaker DJ. Treatment of malignant
mesothelioma. World J Surg 2001;25:210–217.
4. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumo-
nectomy in malignant pleural mesothelioma. A Lung Cancer Study
Group trial. J Thorac Cardiovasc Surg 1991;102:1–9.
5. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after
trimodality therapy for malignant pleural mesothelioma. Ann Thorac
Surg 1997;63:334–338.
6. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins,
extrapleural nodal status, and cell type determine postoperative long-
term survival in trimodality therapy of malignant pleural mesothelioma:
results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54–63;
discussion 63–55.
7. Chan MF, Chui CS, Song Y, et al. A novel radiation therapy technique
for malignant pleural mesothelioma combining electrons with intensity-
modulated photons. Radiother Oncol 2006;79:218–223.
8. Forster KM, Smythe WR, Starkschall G, et al. Intensity-modulated
radiotherapy following extrapleural pneumonectomy for the treatment of
malignant mesothelioma: clinical implementation. Int J Radiat Oncol
Biol Phys 2003;55:606–616.
9. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural
pneumonectomy and intensity-modulated radiation therapy for malig-
nant pleural mesothelioma. Ann Thorac Surg 2007;84:1685–1692; dis-
cussion 1692–1683.
10. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation
after extrapleural pneumonectomy for malignant pleural mesothelioma.
Int J Radiat Oncol Biol Phys 2003;56:1319–1326.
11. Carmichael J, Degraff WG, Gamson J, et al. Radiation sensitivity of human
lung cancer cell lines. Eur J Cancer Clin Oncol 1989;25:527–534.
12. Ahamad A, Stevens CW, Smythe WR, et al. Promising early local control
of malignant pleural mesothelioma following postoperative intensity mod-
ulated radiotherapy (IMRT) to the chest. Cancer J 2003;9:476–484.
13. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of
surgical resection and adjuvant high-dose hemithoracic radiation for malig-
nant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788–795.
14. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated
with intensity-modulated radiation therapy for mesothelioma. Int J
Radiat Oncol Biol Phys 2006;65:640–645.
15. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity
after postoperative intensity-modulated radiotherapy for malignant pleu-
ral mesothelioma. Int J Radiat Oncol Biol Phys 2007;69:350–357.
16. Student (William Sealy Gosset). The probable error of a mean. Biometrika
1908;6:1–25.
17. Allen AM, Schofield D, Hacker F, Court LE, Czerminska M. Restricted
field IMRT dramatically enhances IMRT planning for mesothelioma. Int
J Radiat Oncol Biol Phys 2007;69:1587–1592.
18. Krayenbuehl J, Oertel S, Davis JB, Ciernik IF. Combined photon and
electron three-dimensional conformal versus intensity-modulated radio-
therapy with integrated boost for adjuvant treatment of malignant pleural
mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys
2007;69:1593–1599.
19. Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE.
Coronary artery findings after left-sided compared with right-sided
radiation treatment for early-stage breast cancer. J Clin Oncol 2007;25:
3031–3037.
20. Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and
morbidity in early-stage breast cancer patients after breast-conservation
treatment. J Clin Oncol 2006;24:4100–4106.
21. Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in
inoperable esophageal cancer patients treated with definitive chemora-
diation therapy. Int J Radiat Oncol Biol Phys 2008;70:707–714.
22. Cheng JC, Schultheiss TE, Wong JYC. Impact of drug therapy, radiation
dose, and dose rate on renal toxicty following bone marrow transplan-
tation. Int J Radiat Oncol Biol Phys 2008;71:1436–1443.
Journal of Thoracic Oncology • Volume 4, Number 11, November 2009 Hemithoracic Radiotherapy After EPP
Copyright © 2009 by the International Association for the Study of Lung Cancer 1437
